Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1002/jca.70082 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- The Impact of Lipoprotein Apheresis on Inflammatory Factors: A Systematic Review and Meta‐Analysis Alireza Hatami Masoud Eslami Saeed Aslani Shahab Alizadeh Vasily N. Sukhorukov Sercan Karav Bahman Razi Amirhossein Sahebkar Journal of Clinical Apheresis ABSTRACT Lipoprotein apheresis is a well‐established therapy for patients with dyslipidemia unresponsive to conventional lipid‐lowering strategies. However, its impact on systemic inflammation remains uncertain. This systematic review and meta‐analysis evaluated the effect of apheresis on circulating inflammatory markers, including C‐reactive protein (CRP), high‐sensitivity CRP (hs‐CRP), interleukin‐6 (IL‐6), and tumor necrosis factor‐alpha (TNF‐α). Following PRISMA guidelines, a systematic search of PubMed, Scopus, and ISI Web of Science was conducted up to June 2025. Studies reporting pre‐ and post‐apheresis values for inflammatory markers were included. Standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated. Thirteen publications met inclusion criteria. Meta‐analysis demonstrated that apheresis significantly reduced CRP levels (SMD = −0.31; 95% CI: −0.44 to −0.18; p < 0.001), particularly in long‐term interventions. No significant changes were observed for IL‐6, TNF‐α, or hs‐CRP. In conclusion, apheresis significantly reduces CRP levels, especially with long‐term treatment, suggesting a modest anti‐inflammatory benefit. However, its effects on other markers remain unclear. Larger and high‐quality trials are warranted. 10.1002/jca.70082 http://onlinelibrary.wiley.com/termsAndConditions#vor